Telli, Melinda L. http://orcid.org/0000-0001-7993-1235
Litton, Jennifer K.
Beck, J. Thaddeus
Jones, Jason M.
Andersen, Jay
Mina, Lida A.
Brig, Raymond
Danso, Michael
Yuan, Yuan
Symmans, William F.
Hopkins, Julia F.
Albacker, Lee A.
Abbattista, Antonello
Noonan, Kay
Mata, Marielena
Laird, A. Douglas
Blum, Joanne L.
Funding for this research was provided by:
Pfizer
Article History
Received: 14 March 2024
Accepted: 2 June 2024
First Online: 13 June 2024
Declarations
:
: MLT reports research support (to her institution) from Arvinas, AstraZeneca, Bayer, Blueprint Medicines, Genentech, GlaxoSmithKline, Hummingbird Biosciences, Merck, Novartis, OncoSec Medical, Pfizer, RefleXion, and Replicate; and consulting/advisory fees from AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Genentech/Roche, Gilead, GlaxoSmithKline, Guardant, Merck, Natera, Novartis, OncoSec Medical, Pfizer, and Sanofi-Aventis. JKL reports research support (to her institution) from AstraZeneca, EMD Serono, Genentech, GlaxoSmithKline, Medivation/Pfizer, Merck, Novartis, Pfizer, and Zenith Epigenetics; fees for participation on the speakers’ bureaus for Clinical Care Options, Med Learning Group, Medpage, Medscape, Physicians’ Education Resource, PrIME Oncology, and UpToDate; honoraria and patent/royalty payments from UpToDate; travel fees from Clinical Care Options, Med Learning Group, Medscape, and Physicians’ Education Resource; and consulting/advisory from AstraZeneca, Ayala Pharmaceuticals, Medivation/Pfizer, and Pfizer—all uncompensated. JTB reports research support (to his institution) from AbbVie, Amgen, Ascentage Pharma Group, AstraZeneca, Bayer, Boston Biomedical/Bristol Myers Squibb, Celgene, Daiichi Sankyo, EMD Serono, Evelo Biosciences, Genentech/Roche, GlaxoSmithKline, Hutchison, Immunomedics, Laekna Therapeutics, Lilly, Mirati Therapeutics, Nektar, Novartis, Pfizer, Polynoma, and Seattle Genetics. JMJ has nothing to disclose. JA reports fees for participation on the speakers’ bureaus for AstraZeneca/Daiichi Sankyo, Genentech, Genomic Health, Immunomedics, Novartis, Puma Biotechnology, and Seattle Genetics; and consulting/advisory fees from AstraZeneca/Daiichi Sankyo, Athenex, Biotheranostics, Myriad, Novartis, Pfizer, Puma Biotechnology, and Seattle Genetics. LAM was an employee at Banner MD Anderson Cancer Center at the time these analyses were performed and has nothing to disclose. RB has nothing to disclose. MD reports consulting/advisory fees from Immunomedics, Novartis, Pfizer, and Seattle Genetics; and honoraria from Amgen. YY was an employee of the City of Hope Comprehensive Cancer Center and Beckman Research Institute at the time of these analyses and reports research support from Eisai, Genentech, and Merck; consulting/advisory fees from BCI Pharma, Daiichi Sankyo, Eisai, Genentech, Gilead, Novartis, Pfizer, and Puma Biotechnology; fees for participation on the speakers’ bureaus for AstraZeneca, Daiichi Sankyo/Lilly, Eisai, Genentech, Gilead, Merck, and Pfizer; and fees for expert testimony for Novartis. WFS reports consulting/advisory fees from Almac Diagnostics and Merck; support for travel from Luminex and Merck; stock ownership in Delphi Diagnostics, Eiger BioPharmaceuticals, ISIS Pharmaceuticals, and Nuvera Biosciences; and an uncompensated relationship with Delphi Diagnostics. JFH was an employee of Foundation Medicine, Inc. at the time of these analyses. LAA is an employee of Foundation Medicine, Inc., and a stockholder of Roche Holdings AG. ADL is an employee of Pfizer and may hold Pfizer stock. AA, MM and KN were employees at Pfizer at the time of these analyses. JLB was a physician at Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network at the time these analyses were performed and reports consulting/advisory fees and honoraria from AstraZeneca, Athenex, Inc., Biotheranostics, Inc., Immunomedics, Inc., OncLive, Pfizer, Inc., Puma Biotechnology, Research to Practice, Sanofi, Tempus, and TD2 and participation on the speakers’ bureaus for Pfizer, Inc., and Tempus.
: This study was conducted according to the International Ethical Guidelines for Biomedical Research Involving Human Patients, the International Council for Harmonisation Guidelines for Good Clinical Practice, the 1964 Declaration of Helsinki and its later amendments, and other applicable national and local regulations. The study protocol was reviewed and approved by an institutional review board, ethics committee and research ethics board. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.